Suppr超能文献

复合性弥漫性大B细胞淋巴瘤和外周T细胞淋巴瘤:一例随访两年的病例报告及文献综述

Composite diffuse large B-cell lymphoma and peripheral T-cell lymphoma: a case report with two-year follow-up and literature review.

作者信息

Gu Jiwei, Qian Juan, Cao Xin

机构信息

Department of Hematology, Affiliated Hospital of Nantong University, Nantong, China.

出版信息

Front Oncol. 2024 Mar 11;14:1272209. doi: 10.3389/fonc.2024.1272209. eCollection 2024.

Abstract

Composite lymphoma is an uncommon type of lymphoid malignancy, and those consisting of concurrent diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) in the same organ are rare. Here, we report a case of a 75-year-old male patient admitted to our emergency department with intestinal obstruction presenting with abdominal pain and vomiting. He underwent partial resection of the small intestine under general anesthesia, and subsequent histopathology confirmed the mass to be composite DLBCL and PTCL-NOS. The patient received chemotherapy with a rituximab-based regimen and achieved complete remission (CR). However, the recurrent disease presented with obstruction again ten months after treatment. He refused a second surgery, but salvage treatment was not effective. The patient survived for 20 months after diagnosis. In addition, we did a literature review to understand the clinical features, pathology, treatment, and prognosis of this type of composite lymphoma.

摘要

复合性淋巴瘤是一种罕见的淋巴系统恶性肿瘤,而由同一器官中同时存在弥漫性大B细胞淋巴瘤(DLBCL)和外周T细胞淋巴瘤,非特指型(PTCL-NOS)组成的情况则更为罕见。在此,我们报告一例75岁男性患者,因肠梗阻伴腹痛和呕吐入住我院急诊科。他在全身麻醉下接受了小肠部分切除术,随后的组织病理学检查证实肿块为复合性DLBCL和PTCL-NOS。该患者接受了以利妥昔单抗为基础方案的化疗,并实现了完全缓解(CR)。然而,治疗十个月后复发性疾病再次出现梗阻。他拒绝了二次手术,但挽救治疗无效。该患者确诊后存活了20个月。此外,我们进行了文献综述以了解此类复合性淋巴瘤的临床特征、病理、治疗及预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b26/10961394/7ed772f3958f/fonc-14-1272209-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验